FY2026 EPS Forecast for Kura Oncology Increased by Analyst

Key Points

• Brookline Capital Markets raised its FY2026 EPS forecast for Kura Oncology to a loss of $3.35 per share from a projected loss of $3.48; the analyst also issued estimates for 2027 and 2028.
• Kura reported a quarterly loss of $0.78 per share, beating the $0.82 loss analysts expected, while revenue of $22.84 million fell short of the $24.94 million consensus.
• Analyst sentiment is mixed but leans positive: 11 analysts rate the stock Buy, one Hold and one Sell, producing a “Moderate Buy” consensus and an average target price of $25.88.

Kura Oncology, Inc. (NASDAQ:KURA - Free Report) - Analysts at Brookline Capital Markets lifted their FY2026 EPS estimates for Kura Oncology in a research report issued on Tuesday, November 10th. Brookline Capital Markets analyst L. Cann now anticipates that the company will post earnings of ($3.35) per share for the year, up from their prior estimate of ($3.48). The consensus estimate for Kura Oncology's current full-year earnings is ($3.25) per share. Brookline Capital Markets also issued estimates for Kura Oncology's Q4 2026 earnings at ($0.97) EPS, FY2027 earnings at ($2.47) EPS and FY2028 earnings at ($2.30) EPS.

A number of other equities research analysts have also issued reports on KURA. UBS Group set a $24.00 target price on Kura Oncology in a research report on Thursday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Kura Oncology in a research note on Thursday, October 15th. Barclays set a $24.00 price objective on shares of Kura Oncology in a research note on Wednesday, October 14th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Kura Oncology in a research report on Wednesday, October 14th. Finally, Raymond James Financial set a $24.00 target price on Kura Oncology in a report on Monday, August 24th. Eleven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $25.88.

Kura Oncology Price Performance

KURA stock opened at $7.43 on Friday. The stock has a 50-day moving average price of $10.28 and a two-hundred day moving average price of $9.77. Kura Oncology has a 1 year low of $6.75 and a 1 year high of $13.90. The stock has a market cap of $682.67 million, a PE ratio of -2.25 and a beta of 0.56. The company has a current ratio of 3.60, a quick ratio of 4.71 and a debt-to-equity ratio of 0.07.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its quarterly earnings data on Tuesday, November 10th. The company reported ($0.78) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.82) by $0.04. The company had revenue of $22.84 million during the quarter, compared to the consensus estimate of $24.94 million. Kura Oncology had a negative net margin of 369.26% and a negative return on equity of 336.24%.

Insider Transactions at Kura Oncology

In other Kura Oncology news, insider Mollie Leoni sold 28,802 shares of the company's stock in a transaction that occurred on Tuesday, September 29th. The stock was sold at an average price of $10.75, for a total value of $309,621.50. Following the sale, the insider owned 141,095 shares in the company, valued at $1,516,771.25. This represents a 16.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Brian Powl sold 15,430 shares of the firm's stock in a transaction that occurred on Tuesday, September 29th. The shares were sold at an average price of $10.75, for a total value of $165,872.50. Following the completion of the sale, the insider directly owned 136,819 shares of the company's stock, valued at approximately $1,470,804.25. The trade was a 10.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 153,881 shares of company stock valued at $1,708,183. Company insiders own 7.60% of the company's stock.

Institutional Trading of Kura Oncology

A number of hedge funds have recently modified their holdings of KURA. IFP Advisors Inc increased its position in Kura Oncology by 136.5% during the 2nd quarter. IFP Advisors Inc now owns 2,542 shares of the company's stock worth $28,000 after buying an additional 1,467 shares during the period. Sterling Capital Management LLC grew its stake in shares of Kura Oncology by 842.5% in the third quarter. Sterling Capital Management LLC now owns 2,818 shares of the company's stock valued at $30,000 after acquiring an additional 2,519 shares in the last quarter. Physician Wealth Advisors Inc. acquired a new position in shares of Kura Oncology in the third quarter valued at about $43,000. Mirae Asset Global Investments Co. Ltd. bought a new position in Kura Oncology during the third quarter worth about $49,000. Finally, Allworth Financial LP bought a new position in Kura Oncology during the second quarter worth about $113,000.

Top Kura Oncology Stories

Investors following KURA have been watching these stories:

• Positive Sentiment: Kura said it expects to receive $25 million in funding, which could add financial flexibility. Funding announcement
• Positive Sentiment: Third-quarter results highlighted 53% growth in KOMZIFTI revenue and progress on pipeline plans for 2027, potential commercial and development catalysts. Q3 results and pipeline plans
• Neutral Sentiment: HC Wainwright raised its 2026–2029 EPS forecasts, now projecting smaller losses in each year; Brookline also modestly improved its 2026–2028 estimates. These revisions are supportive, but remain projections rather than evidence that Kura has reached profitability.

About Kura Oncology

Kura Oncology is a biopharmaceutical company focused on developing precision medicines for cancer. Its research has centered on therapies that target molecular pathways involved in tumor growth and blood cancers. The company's best-known program is ziftomenib, an oral menin inhibitor developed for acute myeloid leukemia, including forms associated with NPM1 mutations or KMT2A rearrangements. Kura has also worked on other targeted cancer therapies. Based in San Diego, California, Kura conducts drug development and clinical research in the United States and has worked with international partners to advance its programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.